• AlzeCure reports anti-inflammatory effects with NeuroRestore ACD856 with relevance to Alzheimer's leading to new patent application

  • Communiqué from the annual general meeting of AlzeCure Pharma on 14 May 2024

  • Eli Lilly’s and AstraZeneca’s former head of research Dr. Jan Lundberg elected as a new board member

  • Share Issue 2024

AlzeCure Pharma

AlzeCure Pharma is a Swedish pharmaceutical company focusing on the research and development of innovative and efficacious treatments for Alzheimer’s disease and related disorders

Research

AlzeCure is developing disease modifying and symptomatic first in class treatments for Alzheimer’s disease and other conditions characterized by cognitive dysfunction

Alzheimer’s Disease

Alzheimer’s disease is a deadly disorder which lacks effective treatments. The need for novel treatments is therefore urgent.